右美托咪定对手术患者以患者为中心结局的有效性:系统评价与贝叶斯Meta分析
该系统评价与贝叶斯Meta分析纳入44项RCT共5904例成人全麻手术患者,评估术中右美托咪定对以患者为中心结局的有效性。结果显示右美托咪定可改善术后恢复质量(QoR-15均差9,95%CrI 4-14)并降低慢性疼痛发生率(OR 0.42,95%CrI 0.19-0.79),但可能增加临床显著低血压和心动过缓风险,证据确定性中至极低。
要点
- 术中右美托咪定可能改善术后恢复质量,QoR-15均差9分,达MID概率88%。
- 右美托咪定可能降低慢性疼痛发生率,OR 0.42,但证据确定性低。
- 右美托咪定可能增加临床显著低血压和心动过缓风险,证据确定性极低。
核心结论
- 与安慰剂或标准治疗相比,术中右美托咪定可能显著改善术后恢复质量和慢性疼痛,但可能增加临床显著心动过缓和低血压。
研究设计与样本
- 系统检索MEDLINE、Embase、CENTRAL、Web of Science和CINAHL自建库至2023年10月,纳入44项RCT共5904例成人全麻手术患者,比较术中右美托咪定与安慰剂、阿片类或常规护理。
- 采用随机效应贝叶斯回归框架合成数据,连续结局用标准化均数差(SMD)合并并转换为原量表,使用GRADE评估证据确定性。
主要发现
- 术后QoR-15均差9(95%CrI 4-14,n=21项RCT,中等确定性证据),任何获益概率99%,达到MID概率88%。
- 慢性疼痛发生率降低(OR 0.42,95%CrI 0.19-0.79,n=7项RCT,低确定性证据)。
- 临床显著低血压风险增加(OR 1.98,95%CrI 0.84-3.92, posterior probability of harm 94%,n=8项RCT,极低确定性证据)。
- 临床显著心动过缓风险增加(OR 1.74,95%CrI 0.93-3.34, posterior probability of harm 95%,n=10项RCT,极低确定性证据)。
关键数值与推荐
- 主要结局为术后恢复质量,采用QoR-15量表(范围0-150分,最小重要差异MID为6分)。
- QoR-15均差9分(95%CrI 4-14),达到MID概率88%。
- 慢性疼痛OR 0.42(95%CrI 0.19-0.79)。
- 临床显著低血压OR 1.98(95%CrI 0.84-3.92),损害后验概率94%。
- 临床显著心动过缓OR 1.74(95%CrI 0.93-3.34),损害后验概率95%。
临床怎么用
- 成人全麻手术术中可考虑使用右美托咪定以改善术后恢复质量和降低慢性疼痛风险。
- 使用右美托咪定时应警惕临床显著低血压和心动过缓,需加强血流动力学监测。
局限性
- 低血压和心动过缓结局的证据确定性为极低,解释需谨慎。
- 其他以患者为中心次要结局的证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dexmedetomidine is increasingly used for surgical patients requiring general anaesthesia. However, its effectiveness on patient-centred outcomes remains uncertain. Our main objective was to evaluate the patient-centred effectiveness of intraoperative dexmedetomidine for adult patients requiring surgery under general anaesthesia. METHODS: We conducted a systematic search of MEDLINE, Embase, CENTRAL, Web of Science, and CINAHL from inception to October 2023. Randomised controlled trials (RCTs) comparing intraoperative use of dexmedetomidine with placebo, opioid, or usual care in adult patients requiring surgery under general anaesthesia were included. Study selection, data extraction, and risk of bias assessment were performed by two reviewers independently. We synthesised data using a random-effects Bayesian regression framework to derive effect estimates and the probability of a clinically important effect. For continuous outcomes, we pooled instruments with similar constructs using standardised mean differences (SMDs) and converted SMDs and credible intervals (CrIs) to their original scale when appropriate. We assessed the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. Our primary outcome was quality of recovery after surgery. To guide interpretation on the original scale, the Quality of Recovery-15 (QoR-15) instrument was used (range 0-150 points, minimally important difference [MID] of 6 points). RESULTS: We identified 49,069 citations, from which 44 RCTs involving 5904 participants were eligible. Intraoperative dexmedetomidine administration was associated with improvement in postoperative QoR-15 (mean difference 9, 95% CrI 4-14, n=21 RCTs, moderate certainty of evidence). We found 99% probability of any benefit and 88% probability of achieving the MID. There was a reduction in chronic pain incidence (odds ratio [OR] 0.42, 95% CrI 0.19-0.79, n=7 RCTs, low certainty of evidence). There was also increased risk of clinically significant hypotension (OR 1.98, 95% CrI 0.84-3.92, posterior probability of harm 94%, n=8 RCTs) and clinically significant bradycardia (OR 1.74, 95% CrI 0.93-3.34, posterior probability of harm 95%, n=10 RCTs), with very low certainty of evidence for both. There was limited evidence to inform other secondary patient-centred outcomes. CONCLUSIONS: Compared with placebo or standard of care, intraoperative dexmedetomidine likely results in meaningful improvement in the quality of recovery and chronic pain after surgery. However, it might increase clinically important bradycardia and hypotension. SYSTEMATIC REVIEW PROTOCOL: PROSPERO (CRD42023439896).
引用
- Verret M, Le JBP, Lalu MM, et al. Effectiveness of dexmedetomidine on patient-centred outcomes in surgical patients: a systematic review and Bayesian meta-analysis. Br J Anaesth. 2024. PMID: 39019769. doi:10.1016/j.bja.2024.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。